The RSI Indicator for ALGN moved out of oversold territory on September 16, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In 28 of the 38 cases the stock moved higher. This puts the odds of a move higher at 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 57 cases where ALGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 192 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ALGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 50-day moving average for ALGN moved below the 200-day moving average on September 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.434) is normal, around the industry mean (5.011). P/E Ratio (25.174) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The Moving Average Convergence Divergence (MACD) for ICUI turned positive on September 24, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ICUI's RSI Oscillator exited the oversold zone, 21 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +4.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 193 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICUI as a result. In 63 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
ICUI moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ICUI crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for ICUI entered a downward trend on September 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.906) is normal, around the industry mean (5.011). P/E Ratio (137.840) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
ALGN | ICUI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 89 | |
PRICE GROWTH RATING 1..100 | 62 | 40 | |
P/E GROWTH RATING 1..100 | 25 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALGN's Valuation (63) in the Medical Specialties industry is in the same range as ICUI (73). This means that ALGN’s stock grew similarly to ICUI’s over the last 12 months.
ALGN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ICUI (100). This means that ALGN’s stock grew similarly to ICUI’s over the last 12 months.
ALGN's SMR Rating (69) in the Medical Specialties industry is in the same range as ICUI (89). This means that ALGN’s stock grew similarly to ICUI’s over the last 12 months.
ICUI's Price Growth Rating (40) in the Medical Specialties industry is in the same range as ALGN (62). This means that ICUI’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's P/E Growth Rating (25) in the Medical Specialties industry is significantly better than the same rating for ICUI (100). This means that ALGN’s stock grew significantly faster than ICUI’s over the last 12 months.
| ALGN | ICUI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 66% |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 73% |
| Momentum ODDS (%) | N/A | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 71% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 72% |
| Advances ODDS (%) | 6 days ago 70% | 3 days ago 68% |
| Declines ODDS (%) | 10 days ago 75% | 8 days ago 71% |
| BollingerBands ODDS (%) | 1 day ago 74% | N/A |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 72% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green while ICUI’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 5 TA indicator(s) are bullish while ICUI’s TA Score has 3 bullish TA indicator(s).
ALGN (@Pharmaceuticals: Other) experienced а +1.48% price change this week, while ICUI (@Pharmaceuticals: Other) price change was +2.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.23%. For the same industry, the average monthly price growth was -3.14%, and the average quarterly price growth was +7.32%.
ALGN is expected to report earnings on Oct 28, 2026.
ICUI is expected to report earnings on Nov 09, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| UCO | 60.55 | 1.44 | +2.44% |
| ProShares Ultra Bloomberg Crude Oil (UCO) | |||
| IBDW | 20.08 | -0.02 | -0.10% |
| iShares iBonds Dec 2031 Term Corporate ETF (IBDW) | |||
| FCBD | 24.61 | -0.03 | -0.12% |
| Frontier Asset Core Bond ETF | |||
| BAMG | 45.65 | -0.07 | -0.15% |
| Brookstone Growth Stock ETF (BAMG) | |||
| AIUP | 30.89 | -0.25 | -0.81% |
| Finq First U.S. Large Cap AI Managed Equity ETF | |||
A.I.dvisor indicates that over the last year, ALGN has been closely correlated with NVST. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALGN jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | +2.22% | ||
| NVST - ALGN | 71% Closely correlated | -0.31% | ||
| XRAY - ALGN | 58% Loosely correlated | -0.29% | ||
| LUNG - ALGN | 52% Loosely correlated | -2.22% | ||
| ICUI - ALGN | 50% Loosely correlated | -0.41% | ||
| ILMN - ALGN | 48% Loosely correlated | -1.99% | ||
More | ||||